Shares of earKART Ltd surged sharply on Thursday, October 30, rising 10.22% to Rs 229.80, after the company announced the grant of a patent for its “Smart Sound Treatment and Diagnosis System and Method Thereof” by the Indian Patent Office. The technology combines acoustic signal processing, artificial intelligence (AI) and smart sensors to enable non-invasive medical diagnosis and therapeutic sound-based treatment.
The patent covers a system capable of analysing sound patterns — including respiratory and cardiac signals — to detect health conditions in real-time and deliver targeted audio frequencies or vibrations for therapeutic purposes. The system can also integrate with IoT-based health devices and mobile platforms, expanding potential consumer and clinical applications.
In its exchange filing, earKART said the innovation strengthens its IP portfolio in the digital health space, enhances research and development capabilities, and creates opportunities for commercial deployment, technology licensing and medical collaborations. The company noted that the patent aligns with emerging trends in AI-driven smart healthcare and sound-based wellness systems, positioning it for innovation-led growth in the preventive and diagnostic health technology segment.
Stock performance and market reaction
earKART saw strong buying interest following the announcement, with the stock opening and trading near day highs.
| Metric | Details |
|---|---|
| Price | Rs 229.80 |
| Daily Move | +10.22% |
| Previous Close | Rs 218.90 |
| Market Cap | Rs 3.16 billion |
| P/E Ratio | 6.09 |
| Year Range | Rs 135.50 – Rs 265.95 |
The stock has also been witnessing an uptick in investor attention amid rising interest in digital health, wearable technology, and AI-integrated diagnostics.
Outlook
The company stated that the patent reinforces its focus on AI-enabled sound diagnostics and smart medical solutions, with potential to support non-invasive healthcare adoption in India and global markets. As the business explores commercialisation pathways, investors will track product deployment, partnerships, and regulatory milestones in the digital medical technology space.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
